MedTrace Logo

Clinical Outcomes and Decision-making Choice of Skull Base Approaches for Petroclival Meningiomas

NCT06319664 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 179

Last updated 2024-03-20

No results posted yet for this study

Summary

Petroclival meningioma (PCM) is a technically challenging lesion. We aimed to analyze the role of various skull base approaches and evaluate the therapeutic outcomes guided by the modified classification. We retrospectively analyzed the clinical characteristics, surgical approaches, outcomes and follow-up data from 179 cases of PCM from January 2011 to December 2020. We modified the previous classification into updated five types with two subtypes: clivus type (CV), petroclival type (PC), petroclivosphenoidal type (PC-S), sphenopetroclival type (S-PC) with two subtypes of S-PC I and S-PC II and central skull base type (CSB). Statistical analysis was performed using IBM SPSS Statistical Package 21.0. The t-test was performed to clinical data comparisons between the two groups and the ANOVA test was used to compare the difference between multiple groups. P \< 0.05 was considered statistically significant.

Conditions

  • Skull Base Meningioma

Interventions

PROCEDURE

retrosigmoid approach (RSA)

The skull base approach choice was fundamentally followed by the modified classification.

PROCEDURE

subtemporal transtentorial transpetrosal approach (STTA)

The skull base approach choice was fundamentally followed by the modified classification.

PROCEDURE

extended pterional transtentorial approach (EPTA)

The skull base approach choice was fundamentally followed by the modified classification.

PROCEDURE

pretemporal trancavernous anterior transpetrosal approach (PTCA)

The skull base approach choice was fundamentally followed by the modified classification.

PROCEDURE

presigmoid combined supra-infratentorial approach (PCA)

The skull base approach choice was fundamentally followed by the modified classification.

PROCEDURE

inoperable

The skull base approach choice was fundamentally followed by the modified classification.

Sponsors & Collaborators

  • Xiangya Hospital of Central South University

    lead OTHER

Principal Investigators

  • Qing Liu, MD · Xiangya Hospital of Central South University

Eligibility

Min Age
15 Years
Max Age
73 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-05-27
Primary Completion
2021-08-10
Completion
2021-09-10

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06319664 on ClinicalTrials.gov